Q-omics provides the consensus-scored LINC02182 profile across patient tissues and cancer cell-line models. LINC02182 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC02182 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, LINC02182 RNA expression shows 9,674 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KICH, and TGCT as cancer lineages where LINC02182 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02182 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02182 survival associations across molecular data types. LINC02182 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02182 RNA expression–survival associations across cancer types. High LINC02182 expression shows unfavorable associations in STAD, UCEC and TGCT, but favorable associations in KIRP, THYM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC02182 RNA expression.
This table summarizes LINC02182 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02182. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02182 shows lower tumor expression in KICH and BLCA and higher tumor expression in LUAD, STAD, COAD and CHOL. The KICH box plot shows higher LINC02182 RNA expression in normal versus tumor tissue (log2 FC = −1.692, t-test p < 0.001).
This table shows molecular features associated with LINC02182 in patient tissues and cancer cell lines. In patient samples, LINC02182 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
